CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "ALOGLIPTIN BENZOATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED

石 藥 集 團 有 限 公 司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

"ALOGLIPTIN BENZOATE TABLETS"

OBTAINS DRUG REGISTRATION APPROVAL

The board of directors (the "Board") of CSPC Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the "Alogliptin Benzoate Tablets (25mg)" (the "Product") developed by CSPC Ouyi Pharmaceutical Co., Ltd.*（石藥集團歐意 藥業有限公司）, a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People's Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs.

Alogliptin benzoate is a highly selective inhibitor of dipeptidyl peptidase-4(DPP-4) with anti- diabetic effects. The Product is indicated for the treatment of type 2 diabetes. It can be used alone as an adjuvant to diet and exercise to improve blood sugar control in patients with type 2 diabetes. When using metformin hydrochloride alone is ineffective in controlling blood sugar, the Product can be taken together with metformin hydrochloride to improve blood sugar control in patients with type 2 diabetes on the premise of diet and exercise.

The approval of the Product further enriches the Group's product portfolio for metabolic diseases and offers new option to patients with type 2 diabetes.

By order of the Board

CSPC Pharmaceutical Group Limited

Cai Dongchen

Chairman

Hong Kong, 11 May 2021

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.

• For identification purpose only